Nektar Therapeutics (Nasdaq: NKTR) is expected to report Q4 earnings on Feb. 28. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nektar Therapeutics's revenues will grow 21.2% and EPS will remain in the red.

The average estimate for revenue is $19.1 million. On the bottom line, the average EPS estimate is -$0.45.

Revenue details
Last quarter, Nektar Therapeutics logged revenue of $18.4 million. GAAP reported sales were 32% lower than the prior-year quarter's $27.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, EPS came in at -$0.38. GAAP EPS were -$0.38 for Q3 compared to -$0.21 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 60.7%, 2,070 basis points worse than the prior-year quarter. Operating margin was -178.7%, 9,990 basis points worse than the prior-year quarter. Net margin was -236.5%, 14,760 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $79.2 million. The average EPS estimate is -$1.48.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 199 members out of 229 rating the stock outperform, and 30 members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 44 give Nektar Therapeutics a green thumbs-up, and 13 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $12.36.